[1] CLARK J E, SARAFRAZ N, MARBER M S. Potential of p38-MAPK inhibitors in the treatment of ischaemic heart disease[J]. Pharmacology & Therapeutics, 2007, 116:192-206.
[2] KRISHNA M, NARANG H. The complexity of mitogen-activated protein kinases (MAPK) made simple[J]. Cellular and Molecular Life Sciences, 2008, 65:3525-3544.
[3] PEARSON G, ROBINSON F, BEERS G T, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions[J]. Endocrine Reviews, 2001, 22:153-218.
[4] TERZIS G, SPENGOS K, MASCHER H, et al. The degree of p70 S6k and S6 phosphorylation in human skeletal muscle in response to resistance exercise depends on the training volume[J]. European Journal of Applied Physiology, 2010, 110:835-843.
[5] ZESTER A, GREDINGER E, BENGAL E. p38 mitogen-activated protein kinase pathway promotes skeletal muscle differentiation[J]. The Journal of Biological Chemistry, 1999, 274(8):5193-5200.
[6] SHIN J H, JEONG J Y, JIN Y, et al. p38β MAPK affords cytoprotection against oxidative stress-induced astrocyte apoptosis via induction of αB-crystalline and its anti-apoptotic function[J]. Neuroscience Letters, 2011, 501(3):132-137.
[7] WHITE A, PARGELLIS C A, STUDTS J M, et al. Molecular basis of MAPK-activated protein kinase 2: p38 assembly[J]. Proceedings of the National Academy of Sciences of the USA, 2007, 104:6353-6358.
[8] WILSON K P, FIZGIBBON M J, CARON P R, et al. Crystal structure of p38 mitogen-activated protein kinase[J]. The Journal of Biological Chemistry, 1996, 271(44):27696-27700.
[9] LECHNER C, ZAHLKA M A, GIOT J K, et al. ERK6, a mitogen-activited protein kinase involved in C2C12 myoblast differrntiation[J]. Proceedings of the National Academy of Sciences of the USA, 1996, 93:4355-4359.
[10] TORTORELLA L L, LIN C B, PILCH P F. ERK6 is expressed in a developmentally regulated manner in rodent skeletal muscle[J]. Biochemical and Biophysical Research Communications, 2003, 306:163-168.
[11] BADRINARAYAN P, SASTRY G N. Sequence, structure, and active site analyses of p38 MAP kinase: exploiting DFG-out conformation as a strategy to design new type Ⅱ leads[J]. The Journal of Chemical Information and Modeling, 2011, 51:115-129.
[12] KUMAR N, DEY C S. Restoration of impaired p38 activation by insulin in insulin resistant skeletal muscle cells treated with thiazolidinediones[J]. Molecular and Cellular Biochemistry, 2004, 260:55-64.
[13] PORTA H, CANCINO-RDEZNO A, SOBERN M, et al. Role of MAPK p38 in the cellular responses to pore-forming toxins[J]. Review Article Peptides, 2011, 32:601-606.
[14] ZARUBIN T, HAN J. Activation and signaling of the p38 MAP kinase pathway[J]. Cell Research, 2005, 15:11-18.
[15] KOOK S H, CHOI K C, SON Y O, et al. Involvement of p38 MAPK-mediated signaling in the calpeptin-mediated suppression of myogenic differentiation and fusion in C2C12 cells[J]. Molecular and Cellular Biochemistry, 2008, 310:85-92.
[16] 张勇,邓科.骨骼肌特异性钙蛋白酶与蛋白质降解[J].动物营养学报,2011,23(4):542-545.
[17] KOISTINEN H A, CHIBALIN A V, ZIERATHI J R. Aberrant p38 mitogen-activated protein kinase signaling in skeletal muscle from type 2 diabetic patients[J]. Diabetologia, 2003, 46:1324-1328.
[18] HELMUTH GEHARTL, SUSANN KUMPFL, ARNE ITTNERL, et al. MAPK signaling in cellular metabolism: stress or wellness?[J]. EMBO reports, 2010, 11:834-840[D].
[19] JI G P, LIU D X, LIU J, et al. p38 mitogen-activated protein kinase up- regulates NF-κB transcriptional activation through RelA phosphorylation during stretch-induced myogenesis[J]. Biochemical and Biophysical Research Communications, 2010, 391:547-551.
[20] LEE J, HONG F, KWON S, et al. Activation of p38 MAPK induces cell cycle arrest via inhibition of Raf/ERK pathway during muscle differentiation[J]. Biochemical and Biophysical Research Communications, 2002, 298:765-771.
[21] KEREN A, BENGAL E, FRANK D. p38 MAP kinase regulates the expression of XMyf5 and affects distinct myogenic programs during Xenopus development[J]. Developmental Biology, 2005, 288:73-86.
[22] MILLER A L, WEBB M S, WANG Y, et al. p38 Mitogen-activated protein kinase (MAPK) is a key mediator in glucocorticoid-induced apoptosis of lymphoid cells: correlation between p38 MAPK activation and site-specific phosphorylation of the human glucocorticoid receptor at serine 211[J]. Molecular Endocrinology, 2005, 19:1569-1583.
[23] KEREN A, TAMIR Y, BENGAL E. The p38 MAPK signaling pathway: a major regulator of skeletal muscle development[J]. Molecular and Cellular Endocrinology, 2006, 252:224-230.
[24] WU Z, WOODRING P J, BHAKTA K S. p38 and extracellular signal-regulated kinases regulate the myogenic program at multiple steps[J]. Molecular and Cellular Biology, 2000, 20:3951-3964.
[25] BAEZA-RAJA B, MUNOZ-CANOVES P. p38 MAPK-induced nucler factor-kappa B activity is required for skeletal muscle differentiation: role of interleukin-6[J]. Molecular Biology of the Cell, 2004, 15:2013-2026.
[26] 张勇,孙璀.钙调磷酸酶-活化T细胞核因子信号途径在骨骼肌细胞生长和发育中生理作用的研究进展[J].动物营养学报,2011,23(4):536-54.
[27] 张勇,崔岩.NF-κB在细胞凋亡中的调节作用和应用前景[J].动物营养学报,2011, 23(5):715-719.
[28] LI H, MALHOTRA S, KUMAR A. Nuclear factor-kappa B signaling in skeletal muscle atrophy[J], Journal of molecular medicine, 2008, 86 :1113-1126.
[29] BAEZA-RAJA B, MUNOZ-CANOVES P. p38 MAPK-induced nuclear factor-kappa B activity is required for skeletal muscle differentiation: role of interleukin-6[J]. Molecular Biology of the Cell, 2004, 15:2013–2026.
[30] VANDEN BERGHE W, PLAISANCE S, BOONE E, et al. p38 and extracellular signal-related protein kinase pathways are required for nuclear factor-kappa B p65 transactivation mediated by tumor necrosis factor[J]. The Journal of Biological Chemistry, 1998, 273(6):3285-3290.
